

Article

Not peer-reviewed version

Chronic Obstructive Pulmonary Disease and Long-Term Home Non-Invasive Ventilation: Analysis of a Telematically Controlled Unit

[Marina Galdeano Lozano](#)*, Carmen Fernandez Arias, [Antonio Marin Muñiz](#), Adriana Martin Pascual, Monica Matute Villacis, Irene Aldas Criado, Laura Ricou Rios, [Antoni Rosell](#), Aida Muñoz Ferrer, [Ignasi Garcia-Olivé](#)

Posted Date: 18 February 2025

doi: 10.20944/preprints202502.1167.v1

Keywords: long-term non-invasive home mechanical ventilation; Chronic Obstructive Pulmonary Disease; telemonitoring; chronic hypercapnia; cost-effectiveness; hospital readmission



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Chronic Obstructive Pulmonary Disease and Long-Term Home Non-Invasive Ventilation: Analysis of a Telematically Controlled Unit

Marina Galdeano Lozano ^{1,*}, Carmen Fernandez Arias ¹, Antonio Marin Muñiz ¹,
Adriana Martin Pascual ¹, Monica Matute Villacis ¹, Irene Aldas Criado ², Laura Ricou Rios ¹,
Antoni Rosell ¹, Aida Muñoz Ferrer ¹ and Ignasi Garcia-Olivé ¹

¹ Hospital Universitari Germans Trias i Pujol, Spain

² Catedra Universitat Internacional de Vic, Spain

* Correspondence: marinagaldeano@gmail.com

Abstract: *Objective:* To describe the cohort of telematically monitored COPD patients receiving Long-Term Home Non-Invasive mechanical ventilation. (LTH-NIV), to evaluate the economic impact of the intervention and to determine the existence of clinical or ventilatory variables that are related to the success of the therapy. *Methodology:* Retrospective observational descriptive study of COPD patients with LTH-NIV with telemonitoring between 2019 and 2022. *Results:* 68 patients were included, 73% male. Mean age 71 years. Emphysema 60.3% with a mean obstruction of 42.3%; comorbidity prevalence of OSA was 27.7% and AHT 19.5%. Mean PaCO₂ before starting LTH-NIV was 57 mmHg; after starting therapy it was 46 mmHg. ST mode with the Resmed® Lumis 150 device. The mean IPAP was 17.04 cmH₂O in 98.5%; the mean EPAP was 8.91 cmH₂O. Compliance was 7.66 hours and mean leak was 26.65 L/min. In more than half of the patients the PaCO₂ was reduced by 20% once the therapy was started, which was significantly associated with a good prognosis. Compliant patients have a lower economic cost. The mean cost of the patients is €8,548 (SD €14,662). AHT was the only comorbidity significantly associated with the failure of LTH-NIV. *Conclusions:* PaCO₂ is not the only variable to be taken into account and specific clinical manifestations, obstruction severity, and certain comorbidities may be critical in determining LTH-NIV indication for COPD patients.

Keywords: long-term non-invasive home mechanical ventilation; Chronic Obstructive Pulmonary Disease; telemonitoring; chronic hypercapnia; cost-effectiveness; hospital readmission

1. Introduction

The diagnosis of Chronic Obstructive Pulmonary Disease (COPD) has evolved over the years alongside the use of Non-invasive Mechanical Ventilation (NIMV). As early as 1990, it was shown that bilevel pressure applied non-invasively via a nasobuccal interface in patients with COPD exacerbated by respiratory acidosis reduces the need for orotracheal intubation, admission to the Intensive Care Unit (ICU), hospital mortality as well as the average length of stay, with improved blood gas and correction of pH[1,2]. In the succeeding years, NIV has become the standard of care for this type of patient: the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) establishes the criteria for its indication with a level of evidence A[3].

Currently, Long-term Home Non-Invasive Mechanical Ventilation (LTH-NIV) is conditionally recommended with low evidence. The Spanish COPD Guide (GesEPOC 2021) [3] proposes a personalized approach to treatable traits: among these, LTH-NIV. It is observed that patients with persistent hypercapnia after a COPD exacerbation who require acute NIV have a higher probability of hospital readmission and mortality than those who normalize arterial blood carbon dioxide levels (PaCO₂). Thus, long-term LTH-NIV is indicated in hypercapnic patients with stable COPD and a

history of previous acidotic exacerbations due to its survival benefits, as well as in those who remain hypercapnic 2-4 weeks after an episode of hypercapnic respiratory failure that has required hospital ventilatory support [3]. In turn, the European Respiratory Society offered conditional recommendations on LTH-NIV: the use of LTH-NIV in COPD with stable hypercapnia, after an exacerbation requiring acute NIV, and the use of LTH-NIV configurations aimed at reducing PaCO₂[4]. The American Thoracic Society recommends the use of nocturnal LTH-NIV (with respiratory polygraphs) and advises against starting therapy during a hospital stay but rather doing a re-evaluation 2 to 4 weeks after the resolution of the exacerbation: the consensus being that the main objective in these patients is the normalization of PaCO₂ to improve survival[4–6].

COPD is one of the most prevalent respiratory diseases worldwide, representing a substantial economic burden for healthcare systems. Annual direct costs per patient vary significantly depending on the severity of the disease, from €1,047 in mild cases to €38,820 in the most severe cases[6]. COPD exacerbations represent a substantial proportion of these costs, with values ranging from €194 to €449 in moderate exacerbations, and between €2,373 and €13,046 in severe cases requiring hospitalization[7]. Proper medical control can prevent frequent hospital visits, difficult-to-manage admissions and therefore potentially avoidable health costs[8–12].

In this context, this study describes the cohort of COPD patients treated with LTH-NIV at the Germans Trias y Pujol University Hospital, assesses the economic impact of the intervention on the healthcare provider and seeks to determine the existence of clinical or ventilatory variables that are related to the success of the therapy.

2. Methods

Description of the Unit

The Ventilation Unit at the Germans Trias y Pujol University Hospital is comprised of three outpatient clinics, complemented by telematic monitoring of ventilators and their variables using the Airview Resmed® and Care Orchestrator Phillips Respironics® platforms. In turn, the Intermediate Respiratory Care Unit (UCRI), consisting of 8 individual bays with advanced hemodynamic monitoring, is available for acute patients. NIV titrations and re-titrations in home patients are carried out according to complexity protocols in the pulmonology day hospital, the Multidisciplinary Sleep Unit or during scheduled inpatient admission (Figure 1).

Clinical Management of the Thoracic Area			
Pulmonology Service			
Ventilation Unit			
Home Hospitalization Unit 1 Pulmonologist 1 Nurse	Intermediate Respiratory Care Unit (UCRI) 8 bays Nurse-patient ratio: 1:4 1 Respiratory therapist 3 Specialist doctors On-Site staff	Specialist Outpatient Clinics <ul style="list-style-type: none">Post-discharge consultation from UCRIChronic ventilation consultation (stable)Severe pneumonia consultationTelemonitoring	Multidisciplinary Unit for Motor Neuron Pathology
Monitoring (respiratory and capnography) Nocturnal polygraphy available. Arterial line placement (with SWAN-Ganz catheter capability). Central line placement and pulmonary artery pressure (PAP) measurement.			




Figure 1. Complete structure of the Ventilation Unit. Hemodynamic support, staff, and direct interaction with specific units.

Study design

A retrospective descriptive observational study of 68 COPD patients with LTH-NIV monitored via telemonitoring between the years 2019 and 2022 inclusive. The analysis was carried out using data from the telemonitoring platforms and the patients’ medical history. Sociodemographic variables (age, sex); clinical phenotype (presence of comorbidities: bronchiectasis in imaging tests, Obesity Hypoventilation Syndrome, arterial hypertension, chronic kidney disease, as well as heart failure and presence of obstructive sleep apnea); pulmonary function tests (FEV1 and FVC post-bronchodilator test); arterial blood gas before the start of treatment and in a stable condition; home ventilator titration parameters (respirator model, ventilator mode, date of therapy prescription, IPAP (inspiratory positive airway pressure) and EPAP (expiratory positive airway pressure) parameters, unintentional leas, and type of interface; variables related to the patient's treatment with inhalation therapy; as well as variables related to the care process (hospital admissions, number of visits to the emergency room, outpatient clinic check-ups and mortality) with their corresponding cost (approximated according to the prices published by the health provider).

In the descriptive analysis, means, range (maximum and minimum) and standard deviation were used for the quantitative variables, while the qualitative variables were expressed as percentages. A logistic regression was performed and the relationship between 2 qualitative variables was obtained (taking into account comorbidities as dependent variables to find a direct relationship with associated pathologies) using contingency tables. The Odds Ratio was calculated with its confidence intervals (CI). The significance level was set at $p<0.05$. Statistical analysis was performed using SPSS version 15.0 for Windows.

3. Results

Patient characteristics: The study included 68 patients diagnosed with COPD, of which 50 (73.5%) were male. The mean age was 71 years (SD 10.1) with a range between 55 and 86 years. Emphysema was the predominant clinical phenotype (62.5%) and the mean degree of obstruction of the sample was 42.3% (SD 18%) with a range of 15%-117%; the most prevalent associated comorbidities were OSA and AHT, chronic kidney disease was present, though not significant, as were congestive heart failure (CHF), obesity and bronchiectasis (**Table 1**).

Table 1. Patient Characteristics.

Variable	Sample (N=68)
Demographic Characteristics	
Age	67.4 years (7.9%)
Male	50 (73.5%)
Clinical Characteristics	
Clinical Phenotype	
Emphysema Chronic bronchitis	40 patients (62.5%)

	24 patients (37.5%)
Post-Bronchodilator FEV1	42.3% (18% SD)
Comorbidities:	
Obstructive sleep apnea	
Congestive heart failure	41 patients (27.7%)
Hypertension	36 patients (24.3%)
Bronchiectasis in imaging tests	29 patients (19.5%)
Obesity hypoventilation syndrome	13 patients (19.1%)
Chronic kidney disease	22 patients (14.8%)
	7 patients (8.7%)

Continuous variables are presented as mean (standard deviation), and categorical variables as n (%).

Arterial blood gas characteristics: In the initial review of arterial blood gas at the time of Home Mechanical Ventilation (HMV) indication, the mean PaCO₂ prior to initiating was 57 mmHg (SD 19) [38–81] compared to 46 mmHg (SD 22) [36–68] in a stable situation post-initiation. A significant improvement, defined as a decrease of as a reduction of more than 20% in PaCO₂ with respect to the initial arterial blood gas, was observed in 51.5% of patients.

Characteristics of the non-invasive mechanical ventilation mode: The predominant ventilatory mode used was ST, mostly with the Lumis 150 Resmed® device. In 98.5% of patients, the mean IPAP was 17.04 cmH₂O (SD 5.2) [10 - 24]; The mean EPAP was 8.91 cmH₂O (SD 2.3) [5–13] with no significant differences between clinical phenotypes. The mean compliance was 7.66 hours (SD 7.3) [1.17–13.46] and the mean leak was 26.65 L/min (SD 57.2) [0–116] (**Table 2**).

Table 2. Description and characteristics of variables related to ventilation mode and titration.

Variables	
Device Used: Lumis 150 ResMed	(68 patients, 100%)
Ventilation Mode: ST	68 (98.5%)
Ventilation Mode: iVAPs	2 (1.5%)
Nasal interface	2 (2.8%)
Nasobuccal interface	66 (97.1%)
Average Compliance	7.76 h/day [Range: 1.17–13.46]
Leaks (95th percentile)	26.65 l/min [Range: 0–116]
Emphysema pressure	IPAP mean 17.2 cmH ₂ O [12–23] EPAP mean 9.1 cmH ₂ O [6–13]
Chronic bronchitis pressure	IPAP mean 16.7 cmH ₂ O [13–22] EPAP mean 8.4 cmH ₂ O [5–12]

Predictive capacity of the variables subject to telemonitoring: A relationship was found to be statistically nonsignificant between the degree of obstruction and the improvement of pCO₂ after initiating ventilation (**Table 3**). Only AHT has been significantly associated with the failure of HMV, in turn a close but non-significant relationship is found with OSA. Variables such as pressures used, mean leaks, and compliance were not significantly associated with gasometric improvement after HMV initiation. However, a significant direct relationship was noted between the need for increased IPAP and EPAP and the number of emergency room visits (correlation coefficient of 0.35) and hospital admissions (correlation coefficient of 0.48) with no correlation to mortality.

Table 3. Logistic Regression of PaCO₂ Improvement After the Initiation of HMV, Among the Studied Population and Comorbidities.

Variables	Odds Ratio)	p-value	95% C
Sex	0.4	0.12	0.13
FEV1 (post)	11.72	0.12	0.52
FVC (post)	3.99	0.37	0.19
Initial PaCO ₂	1.18	<0.05	1.08
PaCO ₂ after HMV	0.7	<0.05	0.6
High-risk emphysema	0.85	0.76	0.32
Low-risk emphysema	1.93	0.59	0.17
High-risk bronchitis	2.98	0.13	0.72
Low-risk bronchitis	0.61	0.44	0.18
OSA	0.66	0.41	0.25
CHF	0.88	0.81	0.33
AHT	2.93	<0.05	1.05
Obesity	1.05	0.92	0.37
Bronchiectasis	1.33	0.63	0.41
CKD	6.66	0.08	0.76

Pharmacological characteristics: The specific inhaled treatment of each patient has been assessed, taking into account the use of dual therapy, triple therapy and the need for associated biological drugs. 24 patients are on triple therapy and 44 on dual therapy. No significant relationship was found between dual or triple inhaled therapy and the need to increase ventilatory pressures (IPAP or EPAP) as well as the need for re-titration of these variables. Similarly, no significant relationship was observed with patient survival when inhaled pharmacological treatment was combined with HMV therapy. It was found that those individuals with a lower forced expiratory volume in the first second post-bronchodilator test (FEV1 post) present greater use of triple therapy and a higher number of visits to the emergency room (p 0.013). Table 1.

Economic impact: The study sample recorded 61 hospital admissions due to pulmonary causes, accounting for 48.5% of all hospital admissions to the Pulmonology Department. Likewise, 53 emergency consultations related to pulmonary causes have been recorded, equivalent to 64.7% of the department as a whole. In addition, 489 specialized outpatient consultations were carried out, including the areas of ventilation, COPD and pulmonary hypertension. Two patients died during the study period.

The average cost per patient in the sample analysed was €8,548 (SD €14,662) (Table 4), with a high variability in individual costs: the patient with the highest cost was approximately €91,426, while the lowest cost was €6,614. This difference is mainly attributed to the need for hospital admission, which represents the highest average cost, followed by outpatient consultations and emergency visits.

Table 4. Average Cost per Patient.

Variable	N per Patient	Unit Cost	Average Cost per Patient
Hospital Stay (days)	16 (29.19)	€491	€7,870 (14,349)
Outpatient Visits	7 (4.64)	€66	€491 (308)
Emergency Room Visits	0.80 (1.40)	€231	€186 (323)
Total Cost			€8,548 (14,662)

Variables are presented as mean (standard deviation).

4. Conclusions

Non-invasive Mechanical Ventilation is currently the standard of care for the treatment of patients with acute COPD. The *Global Initiative for Chronic Obstructive Lung Diseases* clearly establishes the indications for therapy with an evidence level of A.

In contrast, LTH-NIV in COPD patients is recommended conditionally with low-level evidence. The GesEPOC guidelines propose it for patients with persistent hypercapnia following an acute exacerbation requiring NIV or for stable hypercapnic patients. Achieving normocapnia implies a reduction in hospital readmissions and mortality, making it thus far the only variable that has been shown to be representative. In addition, both the ERS and the ATS recommend initiating therapy 2-4 weeks post-hospital discharge, rather than during the admission due to acute exacerbation.

The lack of clinical and functional variables associated with the LTH-NIV indication is evident in current guidelines. In our study, we propose chronic obstruction or increased dyspnea as potential indicators for LTH-NIV, rather than gasometric variables alone. Likewise, comorbidities should also be taken into account, and identifying clusters of patients would be an efficient way to indicate the therapy. As discussed below, some of the patients studied in our group did not initially present with marked hypercapnia, but rather associated dyspnea symptoms, improving their quality of life with treatment and night support.

COPD remains one of the most prevalent respiratory pathologies globally and imposes a significant economic burden on healthcare systems. Hospitalisation due to lack of stability, can incur direct annual costs of up to €40,000. Proper medical management and precise therapeutic indications can reduce potentially avoidable health costs, highlighting the importance of follow-up and control protocols.

During our study of COPD patients being monitored via telemonitoring, we observed that the majority are older adult men who show signs of emphysema and moderate obstruction. Almost all of them presented with hypercapnia greater than 54 mmHg at the start of therapy, although some emphysematous individuals initiated therapy without elevated PaCO₂ but with clinical signs such as tachypnea and dyspnea on exertion. OSA and AHT are significant associated comorbidities, and chronic kidney disease, congestive heart failure, obesity and bronchiectasis stand out. AHT indicates the high failure of HMV. Patients with a lower failure rate showed a good response to therapy with LTH-NIV exhibiting a reduction of more than 20% in PaCO₂, as observed in over half the sample.

In terms of healthcare resource usage, nearly half of the patients experienced at least one hospital admission for pulmonary causes, while over half had emergency visits related to pulmonary conditions. Additionally, nearly 500 specialised outpatient consultations were conducted. Mortality has been very low.

The average cost of the patients included in the sample has been €8,548, with a high variability in individual costs: the patient with the highest cost was approximately €91,426, while the lowest cost

generated was €66. Given this significant economic cost, the associated morbidity and mortality and COPD's prevalence, it is worth considering different therapies that can improve stability and increased survival while reducing health costs. The current guidelines focus on gasometric variables alone to indicate LTH-NIV, but this study highlights the importance of considering broader patient characteristics when initiating therapy. The patient is a set of circumstances and each individual may require support at different stages of the disease. Our study indicates that the PaCO₂ variable is not the only manifestation that must be taken into account and that it is important to expand our registry in terms of the start and indication of LTH-NIV in COPD.

References

1. Engstrom CG. Treatment of severe cases of respiratory paralysis by the Engström universal respirator. *Br Med J*. 1954 Sep 18;2(4889):666-9. doi: 10.1136/bmj.2.4889.666. PMID: 13190223; PMCID: PMC2079443.
2. Brochard L, Isabey D, Piquet J, Amaro P, Mancebo J, Messadi AA et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. *N Engl J Med*. 1990 Nov 29;323(22):1523-30. doi: 10.1056/NEJM199011293232204. PMID: 2122253.
3. Global Initiative for Chronic Obstructive Lung Diseases. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2016 report).
4. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico. Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. Borja G. Cosío, Carme Hernández, Eusebi Chiner, Elena Gimeno-Santos, Eulogio Pleguezuelos, Nuria Seijas, David Rigau, José Luis López-Campos, Juan José Soler-Cataluña, Myriam Calle, Marc Miravittles, Ciro Casanova, en nombre del equipo de trabajo de GesEPOC 2021. DOI: 10.1016/j.arbres.2021.08.010
5. Ergan B, Oczkowski S, Rochweg B, et al. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *Eur Respir J* 2019; 54; 1901003 (<https://doi.org/10.1183/13993003.01003-2019>).
6. Madalina Macrea, Simon Oczkowski, Bram Rochweg, Richard D. Branson, Bartolome Celli, John M. Coleman III, Dean R. Hess, Shandra Lee Knight, Jill A. Ohar, Jeremy E. Orr, Amanda J. Piper, Naresh M. Punjabi, Shilpa Rahangdale, Peter J. Wijkstra, Susie Yim-Yeh, M. Bradley Drummond, and Robert L. Owens; on behalf of the American Thoracic Society Assembly on Sleep and Respiratory Neurobiology. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* Vol 202, Iss 4, pp e74–e87, Aug 15, 2020. DOI: 10.1164/rccm.202006-2382ST.
7. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. *Int J Chron Obstruct Pulmon Dis*. 2020 Feb 26;15:439-460. doi: 10.2147/COPD.S234942. eCollection 2020. PMID: 32161455
8. Alvear S, Canteros J, Jara J, Rodríguez P. Costos reales de tratamientos intensivos por paciente y día cama [Real daily costs of patients admitted to public intensive care units]. *Rev Med Chil*. 2013 Feb;141(2):202-8. doi: 10.4067/S0034-98872013000200009.
9. Elpern EH, Silver MR, Rosen RL, Bone RC. The noninvasive respiratory care unit. Patterns of use and financial implications. *Chest*. 1991 Jan;99(1):205-8. doi: 10.1378/chest.99.1.205. PMID: 1898646.
10. Galdeano Lozano M, Alfaro Álvarez JC, Heili Frades S, Parra Macías N, Parra Ordaz O. Mejora en la eficiencia del manejo del paciente ingresado en una unidad de cuidados respiratorios intermedios tras la introducción de un proceso asistencial integrado [Improvement in the efficiency of patient management in an intermediate respiratory care unit following the introduction of an integrated care process.]. *Journal Healthcare Quality Reserach*. 2021 JulAug;36(4):211-216. doi: 10.1016/j.jhq.
11. Duiverman ML, Maagh P, Magnet FS, et al. Impact of high-intensity-NIV on the heart in stable COPD: a randomised crossover pilot study. *Respir Res* 2017; 18: 76. 37.
12. Duiverman ML, Wempe JB, Bladder G, et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. *Respir Res* 2011; 12: 112.

13. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. *Lancet Respir Med* 2014; 2: 698-705.
14. Order of Public Prices in the ICS - Germans Trias. Last viewed: 10/2023.
15. Adler D, Perrig S, Takahashi H, et al. Polysomnography in stable COPD under non-invasive ventilation to reduce patient ventilator asynchrony and morning breathlessness. *Sleep Breath* 2012; 16: 1081-90.
16. Nava S, Navalesi P. Domiciliary noninvasive ventilatory support. In: Similowski T, Whitelaw W, Derenne J : *Clinical Management of chronic obstructive pulmonary disease*. Marcel Dekker, Inc, New-York : 2002 : 813-48.
17. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. A consensus conference report. *Chest* 1999; 116: 521-34.
18. Actualisation 2003 des recommandations de la SPLF sur la prise en charge de la BPCO. *Rev Mal Respir* 2003; 20: 4S1-4S68. 44. Muir J, Levi-Valensi P. When should patients with COPD be ventilated? *Eur J Respir Dis* 1987; 70: 135-9.
19. Tuggey JM, Plant PK, Elliott MW. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD : an economic analysis. *Thorax* 2003; 58 : 867-71.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.